Conjugate of ofloxacin or derivative thereof and PD-1 monoclonal antibody and application thereof

By designing conjugates of ofloxacin derivatives and PD-1 monoclonal antibodies, precise targeting of tumor cells and efficient action of immune cells can be achieved, solving the problems of unsatisfactory response and drug resistance in tumor immunotherapy, improving treatment efficacy and reducing systemic toxicity.

CN119033950AActive Publication Date: 2024-11-29WUHAN UNIV
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202411167577.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-29
Estimated Expiration
2044-08-23

AI Technical Summary

Technical Problem

The response to current tumor immunotherapy is generally unsatisfactory, and many patients develop resistance after ICB treatment. How to develop safe and effective immunotherapy drugs to improve the targeting of tumor treatment and reduce systemic toxicity is a key question.

Method used

We designed conjugates of ofloxacin or its derivatives with PD-1 monoclonal antibodies, and used tumor-targeting peptides and linkers to bind ofloxacin to PD-1 monoclonal antibodies. By leveraging the tumor microenvironment sensitivity, we achieved precise drug release in tumor cells and efficient action on immune cells.

Benefits of technology

It significantly increases drug concentration in tumor tissues, reduces distribution in normal tissues, enhances the targeting and efficiency of tumor treatment, reduces systemic toxicity, and improves the efficacy of immunotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033950A_ABST
    Figure CN119033950A_ABST
Patent Text Reader

Abstract

The invention discloses a conjugate of ofloxacin or a derivative thereof and a PD-1 monoclonal antibody and application of the conjugate, the conjugate comprises a tumor targeting polypeptide, a non-cleavable connexon, a cleavable connexon, ofloxacin or the derivative thereof and a PD-1 monoclonal antibody, the C end of the tumor targeting polypeptide is connected with the ofloxacin or the derivative thereof through the non-cleavable connexon, and the C end of the tumor targeting polypeptide is connected with the PD-1 monoclonal antibody through the cleavable connexon. The N end of the tumor targeting polypeptide is connected with the PD-1 monoclonal antibody through the cleavable connexon. According to the present invention, the targeting property of the ofloxacin, the PD-1 monoclonal antibody and other tumor treatment drugs can be significantly improved, the toxic-side effect of the whole body can be reduced, the tumor immune microenvironment can be improved from multiple aspects, the immune treatment effect can be improved, and the effects of reduction, synergy and toxicity reduction can be provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to a conjugate of ofloxacin or a derivative thereof and PD-1 monoclonal antibody and applications thereof. Background Art

[0002] Peptide-drug conjugate (PDC) is a new type of conjugated drug that can be used as a platform for tumor treatment. It is mainly composed of peptides, linkers and effective loads, and similar to antibody-drug conjugates (ADCs), it can selectively deliver drugs to tumors. The use of targeted peptides to bind to tumor-specific receptors improves cell selectivity and can increase the therapeutic efficacy of drugs. Compared with the monoclonal antibodies of ADCs, the peptides of PDCs are easier to synthesize and purify, have lower costs, lower immunogenicity, and can be quickly cleared by the kidneys to reduce their toxicity. However, the development of new PDCs is still limited due to the lack of targetable receptors.

[0003] Tumor cells and secreted exosomes can express PD-L1 and bind to PD-1 on the surface of T cells, which can inhibit T cells from recognizing and killing tumor cells. In recent years, tumor immunotherapy based on this mechanism has become a research hotspot and has made major breakthroughs. Research on anti-PD-1 / PD-L1 therapy has been proven to be universal for tumors. However, the universality of response based on this therapy is not ideal, and only 10-30% of tumor patients benefit from it. And due to individual differences in tumor patients and the complexity of the tumor itself, many patients develop drug resistance after ICB treatment. Therefore, how to improve immunotherapy is a hot spot and difficulty in this field.

[0004] Therefore, in view of the bottlenecks and shortcomings of existing technologies, it is necessary to develop a drug that can achieve safe and effective immunotherapy for various malignant tumors. Summary of the invention

[0005] The purpose of the present invention is to provide a conjugate of ofloxacin or its derivatives and PD-1 monoclonal antibody and its application. The conjugate combines the targeting peptide with ofloxacin and PD-1 monoclonal antibody. Through this design, the drug can actively identify and accurately locate tumor cells, significantly increase the drug concentration in tumor tissue, and effectively reduce the nonspecific distribution in normal tissues, thereby achieving the accuracy and efficiency of targeted therapy, so as to achieve the purpose of improving the efficacy of immunotherapy and reducing systemic toxicity. .

[0006] In order to solve the above technical problems, the present invention adopts the following technical solutions:

[0007] In the first aspect of the present invention, a conjugate of ofloxacin or its derivatives and PD-1 monoclonal antibody is provided, comprising:

[0008] A tumor targeting polypeptide, a non-cleavable linker, a cleavable linker, ofloxacin or its derivatives, and a PD-1 monoclonal antibody, wherein the C-terminus of the tumor targeting polypeptide is connected to the ofloxacin or its derivatives via the non-cleavable linker, and the N-terminus of the tumor targeting polypeptide is connected to the PD-1 monoclonal antibody via the cleavable linker.

[0009] Further, the ofloxacin or its derivative comprises: one of ofloxacin, a first derivative and a second derivative;

[0010] The first derivatives include quinolone drugs such as norfloxacin, levofloxacin, pefloxacin, enoxacin, ciprofloxacin, lomefloxacin, grepafloxacin, moxifloxacin, moxifloxacin, trovafloxacin, clinafloxacin, sparfloxacin, nemofloxacin malate, and levofloxacin hydrochloride, levofloxacin lactate, levofloxacin sulfate, levofloxacin maleate, levofloxacin propylene ketone derivatives, levofloxacin aldehyde thiosemicarbazone derivatives, ofloxacin α, β-unsaturated ketone derivatives, levofloxacin aldehyde 4-aryl thiosemicarbazone derivatives, bis-fluoroquinolone thiadiazole levofloxacin derivatives, and ofloxacin amide derivatives;

[0011] The second derivative includes ofloxacin or a derivative obtained by combining the fluoroquinolone skeleton in the first derivative with an α, β-unsaturated ketone or amide group.

[0012] Preferably, the ofloxacin or its derivative is selected from compounds having the following typical structure (I) or formula (II):

[0013]

[0014] Furthermore, the tumor targeting polypeptide is selected from one of cell penetrating peptides CPPs or cell targeting peptides CTPs. Cell penetrating peptides are usually selected from Pep-1, Pentratin, PepFact14 and Transportan; cell targeting peptides are usually selected from PEGA, somatostatin analogs, bombesin analogs, RGD peptides, etc.

[0015] Furthermore, the non-cleavable linker will not trigger cleavage due to chemical or enzymatic stimulation. The mechanism of action of the non-cleavable linker is first that the polypeptide / protein is metabolized, leaving the payload-linker fragment, which can escape from the endosome / lysosome, thereby killing tumor cells; the cleavage of the cleavable linker can be enzymatically or chemically mediated, such as changes in pH, and these linkers are characterized by being stable in the blood circulation to prevent premature and nonspecific release of the drug.

[0016] Preferably, the non-cleavable linker is selected from linkers containing an oxime bond or a thioether bond, and the cleavable linker is selected from pH-sensitive (containing a hydrazine bond or an acetaldehyde bond), redox-sensitive (containing glutathione) or enzyme-sensitive (specific peptide chain) linkers.

[0017] Furthermore, the PD-1 monoclonal antibody is selected from one of pembrolizumab, nivolumab, sintilimab, toripalimab, and carrelizumab; and the Fc segment of the PD-1 monoclonal antibody is conjugated to the polypeptide of the cleavable linker.

[0018] In the second aspect of the present invention, a pharmaceutical composition is provided, comprising the conjugate of ofloxacin or its derivatives and PD-1 monoclonal antibody, and medically acceptable excipients.

[0019] In the third aspect of the present invention, provided is the use of the ofloxacin or its derivatives and PD-1 monoclonal antibody conjugate or the pharmaceutical composition in the preparation of anti-tumor drugs.

[0020] Furthermore, the tumor in the anti-tumor drug includes at least one of colon cancer, oral squamous cell carcinoma, and malignant melanoma.

[0021] Furthermore, the dosage form of the anti-tumor drug includes at least one of granules, tablets, pills, capsules, injections and dispersants.

[0022] One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:

[0023] 1. The present invention provides a conjugate of ofloxacin or its derivatives and PD-1 monoclonal antibody and its application. The complex combines a targeting peptide with ofloxacin and PD-1 monoclonal antibody. Through this design, the drug can actively identify and accurately locate tumor cells, significantly increase the drug concentration in tumor tissue, and effectively reduce the nonspecific distribution in normal tissues, thereby achieving the accuracy and efficiency of targeted therapy, so as to achieve the purpose of improving the efficacy of immunotherapy and reducing systemic toxicity.

[0024] 2. The ofloxacin derivative and PD-1 monoclonal antibody polypeptide conjugate has a tumor microenvironment-sensitive linker and can be cleaved in the tumor microenvironment, thereby increasing the concentration of PD-1 monoclonal antibody in the tumor. PD-1 monoclonal antibody can bind to PD-1 on the surface of T cells in the tumor, thereby preventing it from binding to PD-L1 expressed on the tumor surface and tumor-derived exosomes, thereby enabling it to more efficiently identify and kill tumors.

[0025] 3. The ofloxacin derivative and PD1 monoclonal antibody polypeptide conjugate, ofloxacin can be internalized by tumor cells so as to exert anti-tumor effects more efficiently. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0027] Figure 1 This is a structural design diagram of the ofloxacin derivative and PD-1 monoclonal antibody polypeptide conjugate of the present invention;

[0028] Figure 2 This is a schematic diagram of the decomposition of the ofloxacin derivative and PD-1 monoclonal antibody polypeptide conjugate of the present invention;

[0029] Figure 3 This is the number of exosomes released by oral squamous cell carcinoma cells after the ofloxacin derivative and PD-1 monoclonal antibody polypeptide conjugate of the present invention is treated.

[0030] Figure 4 It is the percentage of cell survival rate after the oral squamous cell carcinoma cells are treated with the ofloxacin derivative and PD-1 monoclonal antibody polypeptide conjugate described in the present invention.

[0031] Figure 5 The present invention shows the inhibitory effect of the ofloxacin derivative and PD-1 monoclonal antibody polypeptide conjugate on the growth of oral squamous cell carcinoma in mice.

[0032] Figure 6 This is the effect of the ofloxacin derivative and PD-1 monoclonal antibody polypeptide conjugate described in the present invention on the survival of oral squamous cell carcinoma mice. DETAILED DESCRIPTION

[0033] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.

[0034] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.

[0035] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or obtained by existing methods.

[0036] The following will be combined with examples and experimental data to describe in detail a conjugate of ofloxacin or its derivatives and PD-1 monoclonal antibodies and their applications. If no specific techniques or conditions are specified in the examples, the technical methods or conditions described in the literature, standards and other technical materials in the field or the product instructions are followed. The methods used described in this section, unless otherwise specified, are conventional methods known in the art, and the consumables and reagents used are commercially available unless otherwise specified.

[0037] The general idea of ​​the present invention is as follows;

[0038] Ofloxacin is a fluoroquinolone antibiotic whose fluoroquinolone complex can achieve antitumor activity through poisoning of type II human DNA topoisomerase.

[0039] The inventors of the present application have found that ofloxacin can inhibit signal transduction adaptor molecule 2 (STAM2) to inhibit the expression of tumor PD-L1 and reduce the secretion of tumor cell exosomes. However, the existing use of ofloxacin does not have cell selectivity, which often leads to increased systemic adverse reactions.

[0040] Therefore, ofloxacin combined with PD-1 monoclonal antibody targeted peptide-drug conjugates have attractive prospects for achieving safe and effective immunotherapy for various malignant tumors.

[0041] According to a typical embodiment of the present invention, a conjugate of ofloxacin or its derivatives and PD-1 monoclonal antibody is provided, comprising:

[0042] A tumor targeting polypeptide, a non-cleavable linker, a cleavable linker, ofloxacin or its derivatives, and a PD-1 monoclonal antibody, wherein the C-terminus of the tumor targeting polypeptide is connected to the ofloxacin or its derivatives via the non-cleavable linker, and the N-terminus of the tumor targeting polypeptide is connected to the PD-1 monoclonal antibody via the cleavable linker.

[0043] The present application uses a connecting peptide to couple ofloxacin to a PD-1 monoclonal antibody, and the connecting peptide comprises two parts: a tumor microenvironment-sensitive linker and a tumor targeting peptide. The conjugate can target the tumor part, wherein the linker can respond to the tumor microenvironment breakage, and then release the ofloxacin and PD-1 monoclonal antibodies coupled at both ends, so that they act on tumor cells and immune cells respectively. On the one hand, ofloxacin targets and inhibits the membrane stabilization and exosome secretion of tumor cell PD-L1, and on the other hand, PD-1 monoclonal antibodies bind to PD-1 proteins on the surface of immune cells, further blocking immunosuppressive signals and reactivating the tumor killing effect of the immune system. Ofloxacin or its derivatives can destroy PD-L1 inside cells, and PD1 monoclonal antibodies can target PD-L1 on the cell membrane, resulting in unexpected synergistic effects.

[0044] The main points of preparing a conjugate of ofloxacin or its derivatives and PD-1 monoclonal antibody in the present application are:

[0045] (1) Ofloxacin derivatives: They are characterized by having the same effects as ofloxacin. Their molecules contain the functional active structure of fluoroquinolone drugs and have both antibacterial and antitumor activities.

[0046] (2) Peptide: The targeting part of the conjugate of ofloxacin derivative and PD-1 monoclonal antibody can specifically recognize and bind to receptors or markers on the surface of tumor cells, thereby guiding the conjugate to the tumor microenvironment. It has the advantages of small molecular weight, low immunogenicity, and easy synthesis and modification.

[0047] (3) Linker: In the conjugate of ofloxacin derivative and PD-1 monoclonal antibody, the C-terminal peptide is linked to the ofloxacin derivative, and a non-cleavable linker is used to precisely transport the ofloxacin derivative into tumor cells to exert its drug effect; the N-terminal peptide is linked to the PD-1 monoclonal antibody, and a cleavable linker is used to cause it to break in the tumor microenvironment (pH-sensitive, enzyme-sensitive, reduction-sensitive, and temperature-sensitive), effectively releasing the ofloxacin derivative and PD-1 monoclonal antibody at specific locations to ensure drug concentration.

[0048] (4) PD-1 monoclonal antibody: The drug part that protects immune cells in the tumor microenvironment can be a self-selected chemotherapy drug, radionuclide or other living molecule. Through the delivery system of peptide conjugates, PD-1 monoclonal antibodies can accumulate in high concentrations in the tumor microenvironment, protecting immune cells from tumor cells, thereby enhancing the therapeutic effect.

[0049] Through the above method, the present invention can not only significantly improve the targeting of tumor therapeutic drugs such as ofloxacin and PD-1 monoclonal antibodies, and reduce systemic toxic side effects, but also improve the tumor immune microenvironment from multiple aspects, improve the efficacy of immunotherapy, and play a role in reducing dosage, increasing efficacy, and reducing toxicity.

[0050] Unless otherwise specified, the professional and scientific terms used in this article have the same meanings as those known to those skilled in the art. In addition, any method or material similar or equivalent to the described content can also be used for the implementation of the related technology involved in the present invention.

[0051] Embodiment 1:

[0052] The structural design of a conjugate of ofloxacin derivative and PD-1 monoclonal antibody polypeptide in this embodiment is as follows Figure 1As shown, it mainly includes four parts: (1) an ofloxacin derivative with a functional active structure of fluoroquinolone drugs (with STAM2 functional domain recognition characteristics); (2) a polypeptide with tumor cell targeting (C-terminus -AEQNPIYWARYADWLFTTPLLLLDLALLADADEGT-N-terminus), SEQ ID NO.1; (3) a non-cleavable linker with an oxime bond (the specific structural formula is C=NOH); (4) a cleavable linker with tumor microenvironment enzyme sensitivity (Gly-Phe-Leu-Gly), SEQ ID NO.2; (5) PD-1 monoclonal antibody.

[0053] In the above technical scheme, the tumor-targeting polypeptide has a certain directionality when penetrating the cell membrane, and enters the cytoplasm through the bilayer through the C-terminus. The C-terminus is connected to the ofloxacin derivative through a non-cleavable linker to transport it to the inside of the tumor cell, and the ofloxacin derivative is efficiently released inside the tumor cell through polypeptide degradation; after the targeted polypeptide penetrates the membrane, the N-terminus remains on the outside of the cell, that is, in the tumor microenvironment, and under the catalysis of the enzyme, the cleavable linker Gly-Phe-Leu-Gly connection is broken, effectively releasing the PD-1 antibody targeted to the immune cells.

[0054] The specific preparation method is as follows: the synthesis of the targeting peptide mainly adopts the solid phase peptide synthesis (SPPS) method, and the targeting peptide chain is formed by gradually adding amino acid residues to the solid phase carrier. During the synthesis process, the reaction conditions, such as temperature, pH value and solvent, need to be controlled to ensure the correct folding and functionality of the peptide chain; the linker is connected to the specific position of the targeting peptide to form a targeting peptide-linker complex; ofloxacin or its derivatives are coupled to the non-cleavable linker end, and the PD-1 monoclonal antibody is coupled to the cleavable linker end to form a complete ofloxacin derivative and PD-1 monoclonal antibody polypeptide conjugate.

[0055] The peptide conjugates of ofloxacin derivatives and PD-1 monoclonal antibodies are mainly targeted to tumors by conjugating ofloxacin derivatives and PD-1 monoclonal antibodies with targeting peptides. The ofloxacin derivatives are precisely transported into tumor cells through targeting peptides and non-cleavable linkers. In the tumor microenvironment, the cleavable linker breaks, releasing the PD-1 monoclonal antibodies targeted by immune cells. Figure 2 This method increases the drug concentration in the tumor and reduces the concentration in other normal parts, so as to improve the efficacy of immunotherapy and reduce systemic toxicity.

[0056] Example 2

[0057] The ofloxacin derivative and PD-1 monoclonal antibody polypeptide conjugate obtained in Example 1 was analyzed for its effect on oral squamous cell carcinoma cell exosome release and tumor cell killing.

[0058] 1. The conjugate inhibits the release of exosomes from oral squamous cell carcinoma cells.

[0059] (1) The concentration of the conjugate was studied using cell activity as an auxiliary detection indicator. On the one hand, the conjugate can inhibit oral squamous cell carcinoma CAL27 cells, and on the other hand, the conjugate will not have a toxic effect on normal cells.

[0060] (2) The optimal concentration of the conjugate (preferably in the range of 1 nM to 100 nM, with the specific concentration of 20 nM in this study) was added to CAL27 cells cultured in vitro and treated for 12 hours. The number of CAL27 cell-derived exosomes before and after conjugate treatment was determined by transmission electron microscopy (TEM) and nanoparticle tracking (NTA) method. Figure 3 ), the results showed that the conjugate could significantly inhibit the release of exosomes from oral squamous cell carcinoma CAL27 cells.

[0061] 2. The first linker of the conjugate has a killing effect on oral squamous cell carcinoma cells.

[0062] The optimal concentration of conjugate was added to normal oral mucosal cells and oral squamous cell carcinoma CAL27 cells cultured in vitro and treated for 12 hours. The cells before and after conjugate treatment were analyzed by flow cytometry using the active dye Zombie ( Figure 4 ), the results showed that the conjugate had a certain selective killing effect on oral squamous cell carcinoma CAL27 cells.

[0063] 3. The effect of the ofloxacin derivative and PD-1 monoclonal antibody polypeptide conjugate obtained in Example 1 on the growth of oral squamous cell carcinoma in mice was analyzed.

[0064] (1) A mouse spontaneous oral tumor model was established in C57 mice using the chemical inducer 4NQO. After continuous feeding of 4NQO for 16 weeks, obvious tumor formation was observed in the oral mucosa of mice. The mice with successful induction were randomly divided into groups and then treated with drugs.

[0065] (2) Oral squamous cell carcinoma mice were treated with ofloxacin alone, PD-1 monoclonal antibody alone, and the conjugate of Example 1 of the present invention, respectively. The mice were gavaged with ofloxacin or conjugate (1 mg per mouse) every day for a total of 22 times; anti-PD-1 monoclonal antibody (200 μg per mouse) was injected intraperitoneally every three days for a total of 4 times. 3) Photos were taken to record the changes and size of the white lesions on the tongue of the mice.

[0066] The results are as follows Figure 5 As shown, PD-1 monoclonal antibody treatment alone could not inhibit tumor growth, while conjugate treatment significantly reduced tumor growth and tumor burden ( Figure 5 ), compared with the single PD-1 monoclonal antibody and the single ofloxacin, the conjugate of the present application produced a synergistic effect.

[0067] 4. The effect of the ofloxacin derivative and PD-1 monoclonal antibody polypeptide conjugate obtained in Example 1 on the survival of oral squamous cell carcinoma mice was analyzed. After treating oral squamous cell carcinoma mice according to 1) and 2) of Example 3, the survival time of the mice was recorded.

[0068] The statistical results are as follows Figure 6 As shown, compared with the PD-1 monoclonal antibody alone and ofloxacin alone, the ofloxacin derivative and PD-1 monoclonal antibody polypeptide conjugate treatment of the present application significantly improved the overall survival rate of oral squamous cell carcinoma mice.

[0069] Finally, it should be noted that the terms "comprises," "includes," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements that are inherent to such process, method, article, or apparatus.

[0070] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0071] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A conjugate of ofloxacin or its derivatives and PD-1 monoclonal antibody, characterized in that: include: A tumor targeting polypeptide, a non-cleavable linker, a cleavable linker, ofloxacin or its derivatives, and a PD-1 monoclonal antibody, wherein the C-terminus of the tumor targeting polypeptide is connected to the ofloxacin or its derivatives via the non-cleavable linker, and the N-terminus of the tumor targeting polypeptide is connected to the PD-1 monoclonal antibody via the cleavable linker.

2. The conjugate of ofloxacin or its derivatives and PD-1 monoclonal antibody according to claim 1, characterized in that: The ofloxacin or its derivatives include: one of ofloxacin, a first derivative and a second derivative; The first derivatives include quinolone drugs such as norfloxacin, levofloxacin, pefloxacin, enoxacin, ciprofloxacin, lomefloxacin, grepafloxacin, moxifloxacin, moxifloxacin, trovafloxacin, clinafloxacin, sparfloxacin, nemofloxacin malate, and levofloxacin hydrochloride, levofloxacin lactate, levofloxacin sulfate, levofloxacin maleate, levofloxacin acrylone derivatives, levofloxacin aldehyde thiosemicarbazone derivatives, ofloxacin α, β-unsaturated ketone derivatives, levofloxacin aldehyde 4-aryl thiosemicarbazone derivatives, bis-fluoroquinolone thiadiazole levofloxacin derivatives, and ofloxacin amide derivatives; The second derivative includes ofloxacin or a derivative obtained by combining the fluoroquinolone skeleton in the first derivative with an α, β-unsaturated ketone or amide group.

3. The conjugate of ofloxacin or its derivatives and PD-1 monoclonal antibody according to claim 1, characterized in that: The tumor targeting polypeptide is selected from one of cell penetrating peptides CPPs or cell targeting peptides CTPs.

4. The conjugate of ofloxacin or its derivatives and PD-1 monoclonal antibody according to claim 1, characterized in that: The PD-1 monoclonal antibody is selected from one of pembrolizumab, nivolumab, sintilimab, toripalimab, and carrelizumab; and the Fc segment of the PD-1 monoclonal antibody is conjugated to the polypeptide of the cleavable linker.

5. A pharmaceutical composition, characterized in that The invention comprises the conjugate of ofloxacin or its derivative and PD-1 monoclonal antibody as described in any one of claims 1 to 4, and medically acceptable excipients.

6. Use of the ofloxacin or its derivative and PD-1 monoclonal antibody conjugate according to any one of claims 1 to 4 or the pharmaceutical composition according to claim 5 in the preparation of anti-tumor drugs.

7. The use according to claim 6, characterized in that: The tumor in the anti-tumor drug includes at least one of colon cancer, oral squamous cell carcinoma, and malignant melanoma.

8. The use according to claim 6, characterized in that: The dosage form of the anti-tumor drug includes at least one of granules, tablets, pills, capsules, injections and dispersants.

Citation Information

Patent Citations

  • Composition for regulating and controlling immune response of acidic environments and preparation method and application thereof

    CN112426438A

  • Immune checkpoint inhibitor and application

    CN114652814A

  • Polypeptide drug conjugate for tumor immunotherapy, drug loading system, drug combination system and application

    CN115501322A

  • Targeted XTEN conjugate compositions and methods of making same

    US20180125988A1

  • Peptide-antibody compositions and methods of use thereof

    US20200188528A1